Paolo Corradini
University of Milan
Internal medicineSurgeryOncologyChemistryPolymer chemistryImmunologyLenalidomideMultiple myelomaChemotherapyCyclophosphamideHematopoietic stem cell transplantationLymphomaDexamethasoneRituximabRegimenStem cellTransplantationMedicineBiologyGastroenterology
790Publications
93H-index
20.1kCitations
Publications 776
Newest
#1Anna DoderoH-Index: 21
#2Anna GuidettiH-Index: 16
Last. Annalisa ChiappellaH-Index: 29
view all 23 authors...
Diffuse Large B-Cell Lymphoma (DLBCL) is a heterogeneous disease, including one-third of cases overexpressing MYC and BCL2 proteins (Double Expressor Lymphoma, DEL) and 5-10% of patients with chromosomal rearrangements of MYC, BCL2 and/or BCL-6 (Double/Triple-Hit Lymphomas, DH/TH). TP53 mutations are detected in 20-25% of DEL. We report the efficacy of dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in a series of 122 consecutive patients, including DEL (n=81, 66%), DEL-MYC (n=9, 7%), DEL-BCL2 (n...
Source
#2Alessandra Romano (University of Catania)H-Index: 22
Last. Roberto M. Lemoli (UniGe: University of Genoa)H-Index: 58
view all 39 authors...
COVID-19 is associated with high mortality in patients with haematological malignancies (HM) and rate of seroconversion is unknown. The ITA-HEMA-COV project (NCT04352556) investigated patterns of seroconversion for SARS-CoV-2 IgG in patients with HMs. A total of 237 patients, SARS-CoV-2 PCR-positive with at least one SARS-CoV-2 IgG test performed during their care, entered the analysis. Among these, 62 (26·2%) had myeloid, 121 (51·1%) lymphoid and 54 (22·8%) plasma cell neoplasms. Overall, 69% o...
Source
#1Sergio CortelazzoH-Index: 43
#2Michael MianH-Index: 23
Last. Anna Maria BarbuiH-Index: 25
view all 22 authors...
1 CitationsSource
#2Andreas Günther (CAU: University of Kiel)H-Index: 11
#3Massimo OffidaniH-Index: 58
Last. Stefano Spada (UNITO: University of Turin)H-Index: 13
view all 19 authors...
Background null Combined therapy with carfilzomib, bendamustine, and dexamethasone was evaluated in this multicenter phase 1/2 trial conducted within the European Myeloma Network (EMN09 trial). null Methods null Sixty-three patients with relapsed/refractory multiple myeloma who had received ≥2 lines of prior therapy were included. The phase 1 portion of the study determined the maximum tolerated dose of carfilzomib with bendamustine set at 70 mg/m2 on days 1 and 8. After 8 cycles, responding pat...
Source
#1Jon Salmanton-García (University of Cologne)H-Index: 7
#2Alessandro BuscaH-Index: 35
Last. Philipp Koehler (University of Cologne)H-Index: 18
view all 11 authors...
Source
#1Anna GuidettiH-Index: 16
#2Anna DoderoH-Index: 21
Last. Alessandra AlessiH-Index: 11
view all 11 authors...
Source
#1A. ChiappellaH-Index: 4
#1Annalisa ChiappellaH-Index: 29
Last. Annalisa ArcariH-Index: 13
view all 32 authors...
Source
#1Alessandro PulsoniH-Index: 43
#2Maria Elena Tosti (ISS: Istituto Superiore di Sanità)H-Index: 36
Last. Carola BoccominiH-Index: 13
view all 44 authors...
Background: Early-stage follicular lymphoma (FL) is usually managed with involved field radiotherapy (IFRT), allowing a complete and long lasting eradication of the disease only in 40-50% of patients (pts). The aim of this multicenter phase II prospective study was to evaluate the role of MRD in identifying pts unlikely to be cured by IFRT, for whom an immunotherapy consolidation could improve outcome. Methods: 110 pts with stage I/II FL were enrolled and treated with 24 Gy IFRT. Peripheral bloo...
Source
#1Annalisa ChiappellaH-Index: 29
#1A. ChiappellaH-Index: 4
Last. Patrizia Chiusolo (UCSC: Catholic University of the Sacred Heart)H-Index: 32
view all 16 authors...
Source
#1Peter DregerH-Index: 66
Last. L. CastagnaH-Index: 11
view all 19 authors...
Source